Medifocus Inc. (MDFZF) 0.1174 $MDFZF
Medifocus Inc. Announces Closing of Private Placement
Marketwire Canada - Mon Sep 15, 7:44AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of a private placement of 10,281,250 Units at a price of US$0.16 per Unit for gross proceeds of US$1,645,000. Each Unit is comprised of one common share (a Common Share) and one Series D Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to purchase one additional Common Share at a price of US$0.25 for a period of 36 months following the completion of the offering. If, at any time after the date that is 12 months following the Closing Date, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or its equivalent in U.S. dollars) for at least 20 consecutive trading days, the Company may, within 30 days of such occurrence, provide an expiry acceleration notice to the holders of Series D Warrants and, if it does so, the Series D Warrants will, unless exercised, expire on the 30th day after the acceleration notice is given.
Medifocus, Inc. Announces Financial Results for the Fiscal First Quarter Ending June 30, 2014
Marketwire - Wed Sep 10, 7:45AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), reported its financial results for the fiscal first quarter ending June 30, 2014 which shows a 32% increase in revenues over the prior year's first quarter.
Medifocus Announces Retraction of Prior Press Release
Marketwire - Mon Sep 08, 6:14PM CDT
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) (Medifocus) issued a press release earlier today regarding the initiation of research coverage by SeeThruEquity that inadvertently included a target price from the research report. Medifocus hereby retracts this press release.
SeeThruEquity Initiates Research Coverage on Medifocus Inc. With Target Price of $0.52
Marketwire - Mon Sep 08, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, has initiated coverage on Medifocus, Inc. with a target price of $0.52. The report is available at: http://www.seethruequity.com/.
Medifocus, Inc. Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014
Marketwire - Wed Jul 30, 8:54AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a revenue generating biotechnology company using focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for fiscal year and the fourth fiscal quarter ending March 31, 2014. Sales from its Prolieve(R) Thermodilatation System, reached $5,383,973 for the fiscal year ended March 31, 2014, representing an increase of 198% from the prior year. In July 2012, Medifocus acquired the Prolieve(R) business from Boston Scientific Corporation and recorded revenues of $1,805,969 from Prolieve for the Fiscal Year ended March 31, 2013. The net loss before other charges for the year was $5,222,429, a decrease of $374,043, or 7%, from the previous year primarily due to the revenue growth.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Pr
Marketwire Canada - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Products"
Marketwire - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"
Marketwire Canada - Tue Jul 08, 11:02AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com
Medifocus Inc. Announces Extension of Warrants
Marketwire - Wed Jun 18, 1:29AM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus Inc. Announces Closing of Private Placement
Marketwire Canada - Mon Sep 15, 7:44AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of a private placement of 10,281,250 Units at a price of US$0.16 per Unit for gross proceeds of US$1,645,000. Each Unit is comprised of one common share (a Common Share) and one Series D Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to purchase one additional Common Share at a price of US$0.25 for a period of 36 months following the completion of the offering. If, at any time after the date that is 12 months following the Closing Date, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or its equivalent in U.S. dollars) for at least 20 consecutive trading days, the Company may, within 30 days of such occurrence, provide an expiry acceleration notice to the holders of Series D Warrants and, if it does so, the Series D Warrants will, unless exercised, expire on the 30th day after the acceleration notice is given.
Medifocus, Inc. Announces Financial Results for the Fiscal First Quarter Ending June 30, 2014
Marketwire - Wed Sep 10, 7:45AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), reported its financial results for the fiscal first quarter ending June 30, 2014 which shows a 32% increase in revenues over the prior year's first quarter.
Medifocus Announces Retraction of Prior Press Release
Marketwire - Mon Sep 08, 6:14PM CDT
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) (Medifocus) issued a press release earlier today regarding the initiation of research coverage by SeeThruEquity that inadvertently included a target price from the research report. Medifocus hereby retracts this press release.
SeeThruEquity Initiates Research Coverage on Medifocus Inc. With Target Price of $0.52
Marketwire - Mon Sep 08, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, has initiated coverage on Medifocus, Inc. with a target price of $0.52. The report is available at: http://www.seethruequity.com/.
Medifocus, Inc. Announces Financial Results for the Fiscal Year and Fiscal Fourth Quarter Ending March 31, 2014
Marketwire - Wed Jul 30, 8:54AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a revenue generating biotechnology company using focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for fiscal year and the fourth fiscal quarter ending March 31, 2014. Sales from its Prolieve(R) Thermodilatation System, reached $5,383,973 for the fiscal year ended March 31, 2014, representing an increase of 198% from the prior year. In July 2012, Medifocus acquired the Prolieve(R) business from Boston Scientific Corporation and recorded revenues of $1,805,969 from Prolieve for the Fiscal Year ended March 31, 2013. The net loss before other charges for the year was $5,222,429, a decrease of $374,043, or 7%, from the previous year primarily due to the revenue growth.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Pr
Marketwire Canada - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Is Issued New U.S. Patent Titled, "Apparatus and Method for Pre-Conditioning /Fixation and Treatment of Disease With Heat Activation/Release With Thermoactivated Drugs and Gene Products"
Marketwire - Wed Jul 09, 10:25AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that on July 1st, 2014, it was issued a new patent by the United States Patent and Trademark Office (USPTO). Medifocus owns an extensive and valuable patent portfolio of over 100 USA and International patents all related to the usage and method of heating technologies to treat diseases almost anywhere within the body.
Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"
Marketwire Canada - Tue Jul 08, 11:02AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com
Medifocus Inc. Announces Extension of Warrants
Marketwire - Wed Jun 18, 1:29AM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has applied to the TSX Venture Exchange (the Exchange) to extend the expiry date of 13,056,997 outstanding common share purchase warrants issued pursuant to the private placement announced November 30, 2012 and to extend the expiry date of 22,196,795 outstanding common share purchase warrants issued pursuant to the private placement announced July 6, 2012 by one year. Both sets of warrants entitle the holder thereof to acquire one common share of Medifocus at a price of $0.20.
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
